Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis

Journal of Controlled Release

Volumn 217, Issue , 2015, Pages 221-227

  Tambuwala, Murtaza M ^a   Manresa, Mario C ^b   Cummins, Eoin P ^b   Aversa, Vincenzo ^c   Coulter, Ivan S ^c   Taylor, Cormac T ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Sigmoid Pharma Ltd   (Ireland)

Author keywords

Colitis; Drug delivery; Hydroxylase; Hypoxia; Intestine; Therapeutics

Indexed keywords

CONTROLLED DRUG DELIVERY; DIGESTIVE SYSTEM; DISEASES; DRUG DELIVERY; DRUG DOSAGE; EMULSIFICATION; EMULSIONS;

COLITIS; HYDROXYLASES; HYPOXIA; INTESTINE; THERAPEUTICS;

TARGETED DRUG DELIVERY;

DIMETHYLOXALYLGLYCINE; DRUG CARRIER; MINISPHERE; OXYGENASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; DEXTRAN SULFATE; DICARBOXYLIC AMINO ACID; FIREFLY LUCIFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIXED FUNCTION OXIDASE; OXALYLGLYCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DNA RESPONSIVE ELEMENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG INACTIVATION; DRUG RELEASE; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINAL TISSUE; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLON; DISEASE MODEL; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMINO ACIDS, DICARBOXYLIC; ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HELA CELLS; HUMANS; LUCIFERASES, FIREFLY; MICE; MICE, TRANSGENIC; MIXED FUNCTION OXYGENASES; NF-KAPPA B; TREATMENT OUTCOME;

EID: 84941950636     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.022     Document Type: Article

References (23)

1. E.P. Cummins, and et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity Proc. Natl. Acad. Sci. U. S. A. 103 48 2006 18154 18159
2. W.G. Kaelin Jr., and P.J. Ratcliffe Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway Mol. Cell 30 4 2008 393 402
3. C.M. Taniguchi, and et al. PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2 Sci. Transl. Med. 6 236 2014 236ra64
4. S. Keely, and et al. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis Mucosal Immunol. 7 1 2013 114 123
5. T. Marchbank, and et al. Dimethyloxalyglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms Lab. Investig. 91 12 2011 1684 1694
6. M.L. Hart, and et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor J. Immunol. 186 7 2011 4367 4374
7. P. Hindryckx, and et al. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD J. Immunol. 185 10 2010 6306 6316
8. S.A. Hirota, and et al. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury Gastroenterology 139 1 2010 259 269.e3
9. E.P. Cummins, and et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis Gastroenterology 134 1 2008 156 165
10. A. Robinson, and et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition Gastroenterology 134 1 2008 145 155
11. E.P. Cummins, G.A. Doherty, and C.T. Taylor Hydroxylases as therapeutic targets in inflammatory bowel disease Lab. Investig. 93 4 2013 378 383
12. S.P. Colgan, and C.T. Taylor Hypoxia: an alarm signal during intestinal inflammation Nat. Rev. Gastroenterol. Hepatol. 7 5 2010 281 287
13. C.T. Taylor, and S.P. Colgan Hypoxia and gastrointestinal disease J. Mol. Med. (Berl.) 85 12 2007 1295 1300
14. M.M. Tambuwala, and et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function Gastroenterology 139 6 2010 2093 2101
15. C.C. Scholz, and et al. Regulation of IL-1beta-induced NF-kappaB by hydroxylases links key hypoxic and inflammatory signaling pathways Proc. Natl. Acad. Sci. U. S. A. 110 46 2013 18490 18495
16. S.R. Walmsley, and et al. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice J. Clin. Invest. 121 3 2011 1053 1063
17. E.P. Cummins, G.A. Doherty, and C.T. Taylor Hydroxylases as therapeutic targets in inflammatory bowel disease Lab. Investig. 93 4 2013 378 383
18. S.F. Fitzpatrick, and et al. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia J. Immunol. 186 2 2011 1091 1096
19. C. Zaph, and et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis Nature 446 7135 2007 552 556
20. C.M. Taniguchi, and et al. PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2 Sci. Transl. Med. 6 236 2014 23ra64
21. S. Keely, and et al. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis Mucosal Immunol. 7 1 2014 114 123
22. T. Marchbank, and et al. Dimethyloxalyglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms Lab. Investig. 91 12 2011 1684 1694
23. M.L. Hart, and et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor J. Immunol. 186 7 2011 4367 4374